论文部分内容阅读
目的评价玉屏风散加减联合常规药物治疗单纯疱疹病毒性角膜炎的有效性和安全性。方法通过检索CENTRAL、Pub Med、EMbase、CBM、CNKI、中文科技期刊数据库(VIP)、万方数据库,并获取玉屏风散治疗单纯疱疹病毒性角膜炎的随机对照试验文献,在采用Cochrane偏倚风险评估工具对纳入研究进行方法学质量评估基础上,用Rev Man 5.3软件进行meta分析。结果 10个研究包括955例病例被纳入,meta分析结果表明,玉屏风散加减联合常规药物治疗的疗效优于单纯使用常规药物治疗,RR=1.12(95%CI:1.04,1.21);且复发率也低于常规药物治疗组,RR=0.21(95%CI:0.14,0.30);但倒漏斗图提示可能存在潜在的发表性偏倚。10个研究对不良事件或不良反应报告不充分。结论尽管玉屏风散加减联合常规药物治疗用于单纯疱疹病毒性角膜炎的疗效优于单用常规药物治疗,但所纳入研究的方法学质量较差,结论须谨慎应用。
Objective To evaluate the effectiveness and safety of Yupingfeng Powder combined with conventional drugs in the treatment of herpes simplex virus keratitis. METHODS: Randomized controlled trials of CENTRAL, Pub Med, EMbase, CBM, CNKI, Chinese Science and Technology Database (VIP) and Wanfang database were conducted to obtain the herpes simplex virus keratitis. The Cochrane bias risk assessment Tools Based on the methodological quality of the included studies, a meta-analysis was performed using Rev Man 5.3 software. Results A total of 955 cases were enrolled in 10 studies. The results of meta-analysis showed that Yupingfeng Powder combined with conventional drug treatment was superior to conventional drug treatment only (RR = 1.12, 95% CI: 1.04, 1.21) The RR was also 0.21 (95% CI: 0.14, 0.30), but the inverted funnel suggested a possible potential for publication bias. Ten studies reported inadequate adverse events or adverse reactions. Conclusion Although the Yupingfengsan combined with conventional drug therapy for herpes simplex virus keratitis is superior to the single use of conventional drug therapy, but the methodologies included in the study of poor quality, the conclusion should be carefully applied.